Search / 103 results found

from
to
  • Updated

WEDNESDAY, Jan. 26, 2022 (HealthDay News) -- Booster doses seem effective for the severe acute respiratory syndrome coronavirus 2 omicron variant, according to research published in the Jan. 21 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

  • Updated

TUESDAY, Jan. 25, 2022 (HealthDay News) -- For patients with gout and chronic kidney disease (CKD), no associations with increased mortality were seen for allopurinol initiation, achieving target serum urate (SU) levels, or allopurinol dose escalation, according to a study published online Jan. 25 in the Annals of Internal Medicine.

FRIDAY, Jan. 21, 2022 (HealthDay News) -- Vaccine effectiveness against symptomatic COVID-19 decreases by 20 weeks after the second dose of BNT162b2 or CHAdOx1-S, but limited waning is seen against COVID-19-related hospitalization and death, according to a study published online Jan. 12 in the New England Journal of Medicine.